We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Rituximab in cutaneous B-cell lymphoma: a report of two cases.
- Authors
Sabroe, R.A.; Child, F.J.; Woolford, A.J.; Spittle, M.F.; Russell-Jones, R.
- Abstract
We report two patients with primary cutaneous B-cell lymphoma who were treated with rituximab, a new anti-CD20 monoclonal antibody. The first patient, who had a diffuse large B-cell lymphoma of the lower leg, achieved an 85% improvement. The second patient, who had a primary cutaneous B-cell lymphoma, which had undergone high-grade transformation and systemic spread, achieved a minor response of approximately 30%. Both patients subsequently relapsed. The first patient achieved complete clearance with a second course of rituximab given with systemic chemotherapy, but again relapsed. Treatment with rituximab has been reported to produce response rates of 48% in relapsed systemic low-grade or follicular lymphoma, but there are no previous reports of the use of rituximab in primary cutaneous B-cell lymphoma.
- Subjects
LYMPHOMAS; MONOCLONAL antibodies; B cell lymphoma
- Publication
British Journal of Dermatology, 2000, Vol 143, Issue 1, p157
- ISSN
0007-0963
- Publication type
Article
- DOI
10.1046/j.1365-2133.2000.03607.x